摘要
目的观察本院2010年8月至2012年2月以来收治急性心梗合并心衰32例治疗效果。方法对其中14例患者在常规抗心衰治疗基础上加用重组人脑利钠肽治疗(rh-BNP)设为A组,18例未使用rh-BNP治疗组设为B组。结果 A组无一例出现恶性心律失常和心源性休克,心功能改善明显。复查超声心动图,左室舒张末容积明显降低,左室射血分数有明显增加,B组最终两例死亡,与A组对比有显著性差异。结论提示BNP有较好的临床治疗效果和安全性。
Objective Observed the treatment of 32 cases clinical outcomes,who has acute myocardial infarction complicated by heart failure,since August 2010 to February 2012.Methods 14 patients on the basis of conventional therapy plus recombinant human brain natriuretic peptide therapy（rh-BNP） is set to group A,18 patients was not the use of rh-BNP treatment group is set to group B.Results Group.A.no case ofmalignant arrhythmia and cardiogenic shock,heart function improved significantly.Echocardiography,left ventricular end-diastolic volume significantly decreased left ventricular ejection fraction increased significantly.Group B,the final two cases of death compared with group A were significantly different.Conclusion BNP is better and safety on AMI-AHF.
出处
《中国实用医药》
2012年第23期74-75,共2页
China Practical Medicine
关键词
重组人脑钠利肽(rh-BNP)
心梗后急性左心衰(AMI-AHF)
Recombinant human Brain natriuretic peptide（rhBNP）； Acute myocardial infarction complicated by acute heart failure（AMI-AHF）
